Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716897 · ClinicalTrials.gov registry record · Phase 1
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01716897 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 18 participants.
The verdict
NCT01716897, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.
Interventions
- DRUG E2609
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716897
The ClinicalTrials.gov registry entry for NCT01716897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E2609 is the first listed.
NCT01716897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716897 about?
NCT01716897 is a clinical study titled "An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption". This study will be a single-center, open-label, randomized, 3-treatment crossover study of single oral doses of an API-capsule formulation of E2609 under fasted conditions and a tablet formulation administered under fed and fasted conditions in healthy subjects.
What is the current status of trial NCT01716897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01716897?
The interventions under investigation include: E2609 (DRUG).
Who is sponsoring clinical trial NCT01716897?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.